Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 4/20 | 0.32 |
| ▸ | MAOA | P21397 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323282 | 1.00 | TRPV1 (0.39) | TRPV1KDM1AOPRD1KDM1BHTR2C | |
| SCHEMBL15086539 | 0.85 | TRPV1 (0.39) | TRPV1KDM1AOPRD1KDM1BLMNA | |
| SCHEMBL15086538 | 0.85 | TRPV1 (0.39) | TRPV1KDM1AOPRD1KDM1BLMNA | |
| SCHEMBL20616572 | 0.83 | TRPV1 (0.39) | TRPV1KDM1AOPRD1MAOBMAOA | |
| SCHEMBL15075066 | 0.83 | TRPV1 (0.39) | TRPV1KDM1AOPRD1MAOBMAOA | |
| SCHEMBL3323840 | 0.80 | TRPV1 (0.42) | TRPV1OPRD1MAOBMAOA | |
| SCHEMBL3323847 | 0.80 | TRPV1 (0.42) | TRPV1OPRD1MAOBMAOA | |
| SCHEMBL3327440 | 0.80 | CFTR (0.45) | TRPV1KDM1AHTR2CHTR2B | |
| SCHEMBL3321453 | 0.80 | TRPV1 (0.42) | TRPV1KDM1AKDM1BHTR2CHTR2B | |
| SCHEMBL3327444 | 0.80 | CFTR (0.45) | TRPV1KDM1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212189-B1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE OVERSEAS SÀ RL (LU) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2019-05-02 | — | — | US | disclosed |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE S À R L (LU) | 2017-07-06 | — | — | US | disclosed |
| US-9642831-B2 | Substituted chromanes and method of use | ABBVIE S.Á.R.L. (LU) | 2017-05-09 | — | — | US | disclosed |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE GLOBAL LIMITED (BM) | 2016-05-05 | — | — | US | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8796328-B2 | TRPV1 antagonists | ABBVIE INC. | 2014-08-05 | — | — | US | disclosed |
| US-20130345255-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. | 2013-12-26 | — | — | US | disclosed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885KDM1A 3338/4885OPRD1 43/4885 |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | TRPV1, MRGPRX1, MRGPRX4 | TRPV1 1/4885KDM1A 2848/4885OPRD1 52/4885 |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | TRPV1 1470/4885KDM1A 3952/4885OPRD1 544/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885KDM1A 3414/4885OPRD1 43/4885 |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | TRPV1 1470/4885KDM1A 3952/4885OPRD1 544/4885 |
| US-20130345255-A1 | TRPV1 ANTAGONISTS | TRPV1, NPY1R, OPRL1 | TRPV1 1/4885KDM1A 2853/4885OPRD1 52/4885 |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | CFTR, CHRM3, CHRM2 | TRPV1 1470/4885KDM1A 3952/4885OPRD1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.